Chris Chen, WuXi Biologics CEO (Anthony Kwan/Bloomberg via Getty Images)

WuXi inks $1.5B GSK pact, a big biobuck bet but a blip in bil­lions lost from US un­ver­i­fied list

GSK is tap­ping in­to WuXi Bi­o­log­ics’ T cell-en­gag­ing an­ti­bod­ies in a deal worth as much as $1.5 bil­lion, as the UK …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.